Neisseria gonorrhoeae (Gc) is the sole causative agent of the disease gonorrhea. More than 100 million people are infected annually, and reported infection numbers are consistently on the rise. There are clinical isolates of Gc that have developed resistance to the latest third generation cephalosporins, which is the last recommended line of monotherapy for disease treatment, and there is still no available gonococcal vaccine.Following transmission, Gc comes into contact with host mucosal surfaces. Host epithelial cells recognize the pathogen, and respond by releasing both antimicrobials to combat Gc and proinflammatory cytokines to alert the immune system. The cytokine gradient favors recruitment of large numbers of neutrophils to the site of infection. Neutrophils mount a robust immune response characterized by phagocytosis of Gc, production of reactive oxygen species by NADPH oxidase, formation of NETs and release of antimicrobials that are stored in cytoplasmic granules. Despite the potent immune response, Gc resists complete clearance, which suggests that Gc has defensive mechanisms against killing by neutrophils and host-derived antimicrobials at mucosal surfaces. Herein, I investigated the contribution of two important virulence factors, an LOS-modifying enzyme LptA and a clinically relevant antimicrobial efflux pump MtrCDE, for protection of Gc during interactions with human neutrophils. In addition, I explored the antigonococcal activity of a host-derived antimicrobial, β-defensin 22, and characterized its potential for therapeutic application.Gc interactions with neutrophils are not well understood. Though several important observations by our lab and other groups have advanced our understanding, there are still many unknowns.